File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Febrile neutropenia and its associated hospitalization in breast cancer patients on docetaxel-containing regimen: A retrospective cohort study on duration of prophylactic GCSF administration

TitleFebrile neutropenia and its associated hospitalization in breast cancer patients on docetaxel-containing regimen: A retrospective cohort study on duration of prophylactic GCSF administration
Authors
KeywordsHospitalization
Docetaxel
Prophylaxis
Febrile neutropenia
Breast cancer
GCSF
Issue Date2020
Citation
Supportive Care in Cancer, 2020, v. 28, n. 8, p. 3801-3812 How to Cite?
AbstractPurpose: To compare febrile neutropenia (FN) incidence and hospitalization among breast cancer patients on docetaxel with no granulocyte colony-stimulating factors (GCSF) primary prophylaxis (PP), 4/5-day PP, or 7-day PP. Methods: We identified 3916 breast cancer patients using docetaxel-cyclophosphamide (TC), doxorubicin-cyclophosphamide then docetaxel (AC-T), fluorouracil-epirubicin-cyclophosphamide then docetaxel (FEC-T), docetaxel-carboplatin-trastuzumab (TJH), or docetaxel-doxorubicin-cyclophosphamide (TAC) from a hospital pharmacy dispensing database in Hong Kong between 2014 and 2016. Patients were offered GCSF within 5 days since administering docetaxel. Outcomes included FN incidence, time to first hospitalization, hospitalization rate, and duration. Results: In TC regimen, FN incidence (with odds ratio, OR) of patients with no PP, 4/5-day PP, and 7-day PP was 21.69%, 7.95% (OR 0.31, p < 0.001), and 5.33% (OR 0.20, p < 0.001), respectively. In TJH regimen, FN incidence of patients with no PP, 4/5-day PP, and 7-day PP was 38.26%, 8.33% (OR 0.15, p < 0.001), and 8.57% (OR 0.15, p < 0.001), respectively. FN incidence of patients on AC-T regimen with no PP and 4/5-day PP was 20.93% and 6.84%, respectively (OR 0.28, p = 0.005); with FEC-T regimen, the incidence was 9.91% and 4.77%, respectively (OR 0.46, p = 0.035). Only 3.27% FN cases were not hospitalized. Mean (±standard deviation, SD) time to first hospitalization was 8.21 ± 2.44 days. Mean (±SD) duration of hospitalization for patients with no PP, 4/5-day PP, and 7-day PP was 4.66 ± 2.60, 4.37 ± 2.85, and 5.12 ± 2.97 days, respectively. Conclusion: GCSF prophylaxis in breast cancer patients on docetaxel could reduce FN incidence and hospitalization. 4/5-day PP demonstrated similar efficacy to 7-day PP with superior saving benefits on healthcare expenditure.
Persistent Identifierhttp://hdl.handle.net/10722/303636
ISSN
2023 Impact Factor: 2.8
2023 SCImago Journal Rankings: 1.007
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLee, C. F.-
dc.contributor.authorZhou, K.-
dc.contributor.authorYoung, W. M.-
dc.contributor.authorWong, C. S.-
dc.contributor.authorNg, T. Y.-
dc.contributor.authorLee, S. F.-
dc.contributor.authorLeung, K.-
dc.contributor.authorWong, L. K.M.-
dc.contributor.authorSo, K. H.-
dc.contributor.authorTang, W.-
dc.contributor.authorChong, G.-
dc.contributor.authorChan, S. K.-
dc.contributor.authorYip, Y. T.E.-
dc.contributor.authorMa, V. Y.M.-
dc.contributor.authorYeung, A.-
dc.contributor.authorChin, C. H.Y.-
dc.contributor.authorKwan, M. W.-
dc.contributor.authorTsang, H. T.-
dc.date.accessioned2021-09-15T08:25:43Z-
dc.date.available2021-09-15T08:25:43Z-
dc.date.issued2020-
dc.identifier.citationSupportive Care in Cancer, 2020, v. 28, n. 8, p. 3801-3812-
dc.identifier.issn0941-4355-
dc.identifier.urihttp://hdl.handle.net/10722/303636-
dc.description.abstractPurpose: To compare febrile neutropenia (FN) incidence and hospitalization among breast cancer patients on docetaxel with no granulocyte colony-stimulating factors (GCSF) primary prophylaxis (PP), 4/5-day PP, or 7-day PP. Methods: We identified 3916 breast cancer patients using docetaxel-cyclophosphamide (TC), doxorubicin-cyclophosphamide then docetaxel (AC-T), fluorouracil-epirubicin-cyclophosphamide then docetaxel (FEC-T), docetaxel-carboplatin-trastuzumab (TJH), or docetaxel-doxorubicin-cyclophosphamide (TAC) from a hospital pharmacy dispensing database in Hong Kong between 2014 and 2016. Patients were offered GCSF within 5 days since administering docetaxel. Outcomes included FN incidence, time to first hospitalization, hospitalization rate, and duration. Results: In TC regimen, FN incidence (with odds ratio, OR) of patients with no PP, 4/5-day PP, and 7-day PP was 21.69%, 7.95% (OR 0.31, p < 0.001), and 5.33% (OR 0.20, p < 0.001), respectively. In TJH regimen, FN incidence of patients with no PP, 4/5-day PP, and 7-day PP was 38.26%, 8.33% (OR 0.15, p < 0.001), and 8.57% (OR 0.15, p < 0.001), respectively. FN incidence of patients on AC-T regimen with no PP and 4/5-day PP was 20.93% and 6.84%, respectively (OR 0.28, p = 0.005); with FEC-T regimen, the incidence was 9.91% and 4.77%, respectively (OR 0.46, p = 0.035). Only 3.27% FN cases were not hospitalized. Mean (±standard deviation, SD) time to first hospitalization was 8.21 ± 2.44 days. Mean (±SD) duration of hospitalization for patients with no PP, 4/5-day PP, and 7-day PP was 4.66 ± 2.60, 4.37 ± 2.85, and 5.12 ± 2.97 days, respectively. Conclusion: GCSF prophylaxis in breast cancer patients on docetaxel could reduce FN incidence and hospitalization. 4/5-day PP demonstrated similar efficacy to 7-day PP with superior saving benefits on healthcare expenditure.-
dc.languageeng-
dc.relation.ispartofSupportive Care in Cancer-
dc.subjectHospitalization-
dc.subjectDocetaxel-
dc.subjectProphylaxis-
dc.subjectFebrile neutropenia-
dc.subjectBreast cancer-
dc.subjectGCSF-
dc.titleFebrile neutropenia and its associated hospitalization in breast cancer patients on docetaxel-containing regimen: A retrospective cohort study on duration of prophylactic GCSF administration-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00520-019-05111-6-
dc.identifier.pmid31832822-
dc.identifier.scopuseid_2-s2.0-85076527276-
dc.identifier.volume28-
dc.identifier.issue8-
dc.identifier.spage3801-
dc.identifier.epage3812-
dc.identifier.eissn1433-7339-
dc.identifier.isiWOS:000543089300035-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats